OTC Markets OTCPK - Delayed Quote USD

Ascentage Pharma Group International (ASPHF)

Compare
2.6900
0.0000
(0.00%)
At close: December 4 at 3:00:00 PM EST
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for ASPHF

Recent News: ASPHF

View More

Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
GlobeNewswire 3 days ago
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference

Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
PR Newswire last month
Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months

Live from ASH 2024 | Oral Report Features Encouraging Data of Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in R/R MM, Including a Median PFS Over 9 Months
PR Newswire last month
Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety

Live from ASH 2024 | Ascentage Pharma Releases Updated Data of Bcl-2 Inhibitor Lisaftoclax in MDS that Demonstrates Potential Clinical Benefits and Favorable Safety
PR Newswire last month
Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib

Live from ASH 2024 | 1.5-Year Follow-Up Data from a Global Study of Olverembatinib Reaffirms Potential in Overcoming Resistance/Intolerance to Ponatinib or Asciminib
PR Newswire last month
Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax

Live from ASH 2024 | Ascentage Pharma's Bcl-2 Inhibitor Lisaftoclax in Combinations Demonstrates Potential Clinical Benefit in Patients with Prior Exposure to Venetoclax
PR Newswire last month
Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report

Live from ASH 2024 | First Dataset of Olverembatinib as Second-Line Therapy in Patients with Non-T315I-Mutant CP-CML Presented in Oral Report
PR Newswire last month
Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL

Live from ASH 2024 | First Dataset of Olverembatinib in Combination with Bcl-2 Inhibitor Lisaftoclax Demonstrates Potential Clinical Benefits as a Chemotherapy-Free Regimen for Children with R/R Ph+ ALL
PR Newswire last month
New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List

New Indication of Olverembatinib Included into China 2024 National Reimbursement Drug List
PR Newswire last month
Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors
PR Newswire 2 months ago
Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology
PR Newswire 2 months ago
View More

Related Tickers

2126.HK JW (Cayman) Therapeutics Co. Ltd
1.400
+1.45%
 
BT3.BE Lineage Cell Therapeutics Inc
0.5850
0.00%
 
471A.F aTyr Pharma, Inc.
3.4200
+1.18%
 
CVAC.VI CureVac N.V.
3.6080
-3.84%
 
1GDA.F Zevra Therapeutics, Inc.
7.40
-3.27%
 
HQ1.MU Oruka Therapeutics Inc. R
11.80
-3.28%
 
2Q5.BE Enochian BioSciences Inc
0.8460
-0.24%
 
PH4.F CStone Pharmaceuticals
0.2860
0.00%
 
ORN.F Oryzon Genomics S.A.
1.4660
+3.97%
 
IVBIY Innovent Biologics Inc.
19.15
0.00%